AstraZeneca plc Has a Rocky First-Quarter: Here's What You Need to Know
AstraZeneca reported another tough quarter today, reflecting the loss of exclusivity for top-selling drugs such as Nexium. Even so, there were some important developments and bright spots during the quarter.
Illumina's Earnings Set Positive Tone for Biotech
What's behind Illumina's remarkable earnings beat, and what could it mean for biotech stocks?
Stocks: 6 things to know before the open
Premarkets: 6 things to know before the open
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?